TheraRadar
Public roadmap

What we're building

Live status of every TheraRadar feature. Updates as we ship. No vapor — items only move to "Up next" or "In progress" when we have a real start date.

Shipped

8
Mobile-friendly redesign

Hamburger nav, responsive grids, touch-friendly filter accordions across every page.

2026-04-14
New brand + logo system

Pulse glyph favicon, Thera/Radar wordmark in teal, monochrome slate palette, updated OG image.

2026-04-14
Drug Explorer charts

Approvals by year, modality breakdown, patent cliff timeline, route of administration, area × modality heatmap. PNG download.

2026-04-13
Trials Explorer with precomputed analytics

Search 146,000 trials with a competitive landscape bar showing exact percentages from precomputed slices.

2026-04-13
Patent cliff with revenue arcs

Humira, Stelara, Revlimid, Tecfidera, Januvia, Lantus — actual SEC revenue declines, not Medicare proxies.

2026-04-10
Landing page redesign + public roadmap

New hero, persona-first layout, brand-aligned visuals, public roadmap (this page), contact CTAs.

2026-04-14
Free/Pro split rebalance — dashboards gated

9 deep-analytics dashboards (Pipeline Health, Whitespace, Density, Landscape, Trends, Patent Cliff, Portfolios, Compare, Acquisition Watch) moved to Pro. Free tier keeps the 8 top-of-funnel dashboards (PDUFA, Trials Explorer, etc.).

2026-04-14
Pricing page rewrite

Full rewrite with accurate feature inventory, yearly option ($990/yr, 2 months free), limited-time launch pricing, new comparison table, FAQ refresh.

2026-04-14

In progress

0

Nothing in progress right now.

Up next

2
Phase 3 readout calendar

Global view of upcoming Phase 3 trial readouts across all biotech, color-coded by urgency. Same calendar style as PDUFA.

More target landscape pages

Generate competitive landscapes for hot oncology targets — CDH17, KRAS G12C/G12D, Claudin 18.2, GPRC5D, FAP, MSLN, B7-H3, DLL3, NECTIN-4.

📋

Planned

4
Drug-to-drug compare tool

Side-by-side comparison of any two drugs — clinical profile, indications, trial activity, patent expiry, revenue.

Trial-status alerts via email

Get notified when a watched drug enters a new trial phase or has a primary completion date approaching.

TheraRadar Brief newsletter

Biweekly email: FDA decisions, patent cliffs, and pipeline signals. Published as web pages at /briefs/ as well.

Approval probability score

ML-derived probability of FDA approval for any Phase 3 drug, based on therapeutic area, modality, sponsor, biomarker, and trial design.

Have a feature you want?

We read every suggestion. The best ones end up in the "Up next" column above — usually within a sprint or two of the first mention.

Suggest a feature →

Opens your email client with a short template. Or email hello@theraradar.com directly.

How this works

  • Shipped — features that are live in production today. Click around the site to use them.
  • In progress — actively being built. Usually ships within 1-2 weeks of appearing here.
  • Up next — confirmed next workstream. Will move to "In progress" within the next sprint.
  • Planned — committed to this quarter. Order may shift based on what users tell us matters most.